Company Presentation

AC BioScience has achieved a breakthrough discovery with its new and proprietary immunomodulating molecule ACB2112. In combination treatments with ICIs, ACB2112 potentiates the therapeutic benefits in resistant mouse models (CT26) in colorectal cancer. Its unique MoA is effectively targeting the main mechanisms of immune escape and is enabling MSI-L/MSS patients to respond to the therapy. The company now raises CHF 5M to progress our lead molecule to the clinic.